2017 saw the emergence of a new era in renoprotective medicine for diabetic kidney disease with reports of promising renal outcomes with the sodium–glucose cotransporter 2 (SGLT2) inhibitors empagliflozin and canagliflozin from follow-up analyses of the EMPA-REG OUTCOME trial and the CANVAS Program, respectively, and with use of the glucagon-like peptide 1 (GLP1) agonist liraglutide in the LEADER trial.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).
Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861–869 (2001).
Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).
Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).
Mann, J. F. E. et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839–848 (2017).
Vallon, V. & Thomson, S. C. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60, 215–225 (2017).
Wanner, C. et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease. Circulation https://doi.org/10.1161/CIRCULATIONAHA.117.028268, (2017).
Cherney, D. Z. I. et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 5, 610–621 (2017).
C.W. has received honoraria for consultancy and speaking from Boehringer-Ingelheim, Sanofi-Genzyme, Astra-Zeneca and Mitsubishi Pharma.
About this article
Cite this article
Wanner, C. A new era in therapeutics for diabetic kidney disease. Nat Rev Nephrol 14, 78–80 (2018). https://doi.org/10.1038/nrneph.2017.182
Variability in the incidence of renal replacement therapy over time in Western industrialized countries: A retrospective registry analysis
PLOS ONE (2020)
The results and the meaning of EMPA-REG OUTCOME and LEADER studies for modern diabetology: in search of ideal combination
Medical Council (2019)
Nephrology Dialysis Transplantation (2019)
Diabetes & Metabolic Syndrome: Clinical Research & Reviews (2019)
Der Diabetologe (2018)